Amicus Therapeutics, Inc.

( )
FOLD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 1.63%150.800.0%$1866.71m
NVAXNovavax, Inc. -0.28%220.8992.9%$1381.14m
OCGNOcugen, Inc. -1.25%7.900.0%$852.27m
AMGNAmgen, Inc. 0.52%228.711.3%$603.58m
ILMNIllumina, Inc. 0.30%447.203.5%$556.66m
REGNRegeneron Pharmaceuticals, Inc. 0.49%455.432.7%$534.26m
VRTXVertex Pharmaceuticals, Inc. -0.04%212.891.9%$510.61m
GILDGilead Sciences, Inc. 0.05%62.821.0%$495.12m
BNGOBioNano Genomics, Inc. -3.19%9.700.0%$393.62m
ALXNAlexion Pharmaceuticals, Inc. -0.24%153.282.0%$384.03m
BIIBBiogen, Inc. 0.33%278.161.7%$381.70m
CRSPCRISPR Therapeutics AG -2.58%124.000.6%$294.17m
EXASEXACT Sciences Corp. -2.11%128.5318.4%$241.01m
SRNESorrento Therapeutics, Inc. -0.89%10.031.3%$237.61m
VXRTVaxart, Inc. -2.40%7.320.0%$218.71m

Company Profile

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with rare metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Cranbury, NJ.